Business Context and Reporting Period
This Form 8-K filing by Denali Therapeutics Inc. covers the date of December 12, 2017. The report documents the completion of the Company's Initial Public Offering (IPO) and the associated corporate governance updates required for public listing.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. As a biotechnology company in its IPO phase, the primary financial event reported is the capital raised through the offering.
- Shares Sold: 15,972,221 shares of common stock.
- Over-Allotment: Includes 2,083,333 shares sold pursuant to the full exercise of the underwriters' option.
Material Changes
The most significant material change is the transition from a private to a public company. Specific changes include:
- Capital Structure: Issuance of approximately 16 million shares of common stock.
- Corporate Governance: Filing of an Amended and Restated Certificate of Incorporation and adoption of Amended and Restated Bylaws, effective immediately prior to the IPO completion.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors. The document references the Company's Prospectus (filed December 8, 2017) for detailed descriptions of risk factors and capital stock. No unusual items or contingencies are disclosed within the text of this specific 8-K.
Investor Verification Checklist
- Verify the final IPO share price and total gross proceeds in the attached Press Release (Exhibit 99.1) or the Prospectus.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for voting rights and governance provisions.
- Consult the Prospectus filed on December 8, 2017, for detailed risk factors and use of proceeds.
- Confirm the post-IPO share count and dilution impact on existing shareholders.